Authors
Latest:
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head MassRohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Latest:
Frontline Forum: Real-World Practice in Newly Diagnosed Multiple MyelomaExperts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Latest:
Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025Panelists discuss key strides made in 2024, including exciting data presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024), and reflect on pivotal developments, such as new insights into Bruton tyrosine kinase inhibitors, that are shaping clinical practice while looking ahead to 2025 with anticipation for continued advancements that will further enhance treatment strategies and patient outcomes.
Latest:
Frontline Setting of Pancreatic CancerPanelists discuss how the frontline treatment of pancreatic cancer typically involves chemotherapy regimens such as FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) or gemcitabine-based therapies, with decisions guided by tumor characteristics, patient performance status, and treatment goals, aiming to improve survival outcomes and quality of life in newly diagnosed patients.
Latest:
Adverse Effects Associated with SBRT in Patients With HCCThe panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.
Latest:
The Role of Next-Generation Sequencing in Patients With Neuroendocrine TumorsPanelists discuss how next-generation sequencing can identify actionable mutations and molecular alterations in neuroendocrine tumors, potentially guiding personalized treatment decisions and clinical trial eligibility while advancing our understanding of tumor biology.
Latest:
Optimizing EGFR-Mutant NSCLC Care: Future DirectionsClosing insights into managing EGFR-mutant NSCLC, from evolving treatment options and sequencing strategies to addressing unmet needs and the importance of comprehensive genomic testing.
Latest:
Disorders of Sex Development and Malignant Germ Cell TumorsKey points: Patients with disorders of sex development (DSDs) are at an increased risk of malignant germ cell tumors (GCTs). In adulthood, the partial form of androgen insensitivity syndrome confers the greatest risk of developing malignant GCTs. Gonadoblastoma is the most common gonadal GCT arising in patients with DSDs. Despite being a benign neoplasm, it can undergo malignant transformation in up to 60% of patients with a DSD. Oncologic treatment in patients with disorders of sex development and malignant GCTs does not differ from the standard treatment for testicular GCTs. Treatment of patients with DSDs requires a multidisciplinary team, including a psychiatric, genetic, and reproductive assessment as well as the involvement of an ethics committee. An early diagnosis of DSDs is crucial to avoid the development of potentially serious complications in adulthood.
Latest:
The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant ChemotherapyExperts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Latest:
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic DiseasesA panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
Latest:
Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and CancerHuman saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.
Latest:
Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRCJagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.
Latest:
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: “Dazed and Confused”This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.
Latest:
Exciting Developments in the Pipeline in HER2+ MBCA multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
